Liver Cancer News
Click on the title to read the rest of the Liver Cancer News story.
Marijuana Could Help Protect Alcoholics From Liver Damage
30 January 2018
“Our study revealed that among alcohol users, individuals who additionally use cannabis (dependent and non-dependent cannabis use) showed significantly lower odds of developing alcoholic steatosis (AS), steatohepatitis (AH), cirrhosis (AC) and Hepatocellular Carcinoma (HCC),” the study reads, according to BGR.
Exelixis: Cabozantinib Shows Better Efficacy Profile Than Competition
30 January 2018
It is approved for advanced renal cell carcinoma, metastatic thyroid cancer and is undergoing trials for Hepatocellular Carcinoma. Recently, Exelixis and partner Ipsen reported strong results for cabozantinib in Hepatocellular Carcinoma (HCC), a new indication, bringing the fight even closer to the likes of sorafenib (Nexavar).
Dr. Zhu Discusses Findings Of The KEYNOTE-224 In HCC
29 January 2018
Andrew Zhu, MD, PhD, directory, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the findings of KEYNOTE-224 in Hepatocellular Carcinoma (HCC). KEYNOTE-224 evaluated pembrolizumab (Keytruda) in patients with advanced HCC who had been previously treated with sorafenib (Nexavar).
2018 Gastrointestinal Cancers Symposium Highlights
29 January 2018
In Hepatocellular Carcinoma, phase III findings of the CELESTIAL trial presented during the meeting showed that treatment with cabozantinib improved median overall survival by 2.2 months versus placebo for patients with previously treated advanced disease.
Small-For-Size Graft In Liver Transplantation Outside Milan Criteria Presents Worse Outcomes
29 January 2018
Patients who received small-for-size grafts during liver transplantation for Hepatocellular Carcinoma outside Milan criteria had worse rates of recurrence and survival compared with patients within Milan criteria, according to a recently published study.
New AASLD Guideline Focuses On Improving Diagnosis, Treatment Of Liver Cancer And NAFLD
27 January 2018
A new Practice Guideline and Practice Guidance in Hepatology will help improve the diagnosis and treatment of patients with liver cancer as well as patients with non-alcoholic fatty liver disease (NAFLD), which can lead to liver cancer and is characterized by the build-up of extra fat in liver cells often due to obesity and diabetes.
Losing Your Parents When You Know Nothing Of Death: Solace And Sorrow In The Dead Parent’s Society
26 January 2018
A doctor would run a pen along each line of Mum’s oncologist report, in a few months’ time, pausing to translate the jargon. Primary Hepatocellular Carcinoma (liver cancer) and invasive ductal carcinoma (breast cancer) had resulted in metastatic intraspinal extradural tumors (spinal cancer).
Pembrolizumab Elicits Promising Activity In HCC Patients Previously Treated With Sorafenib
25 January 2018
In phase II data reported at the 2018 Gastrointestinal Cancers Symposium, treatment with the PD-1 inhibitor pembrolizumab (Keytruda) elicited promising progression-free survival (PFS) and overall survival (OS) results in patients with advanced Hepatocellular Carcinoma (HCC) who received previous treatment with sorafenib.
Liver Cancer – Identifying And Commercializing First-In-Class Innovation Market Report
25 January 2018
Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapies is limited; the market consisted entirely of chemotherapies for many years, and only recently have targeted therapies begun to emerge.
Radiofrequency Ablation Improves Survival Over SBRT In Localized HCC
24 January 2018
Radiofrequency ablation (RFA) was associated with superior five-year overall survival (OS) compared with stereotactic body radiotherapy (SBRT) for patients with localized Hepatocellular Carcinoma, according to an observational study published in the Journal of Clinical Oncology.
Merck Reports Positive Phase III Liver Cancer Data On Keytruda
22 January 2018
Merck & Co., Inc. announced data from the phase II KEYNOTE-224 study evaluating the use of its anti-PD-1 therapy, Keytruda in patients with advanced Hepatocellular Carcinoma (HCC), a form of liver cancer, who were previously treated with systemic therapy (sorafenib). The data showed that treatment with Keytruda monotherapy led to an overall response rate (ORR) of 16.3%.
Hepatocellular Carcinoma HCC Treatment Market To Receive Overwhelming Hike In Revenues
22 January 2018
Hepatocellular Carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon Hepatocellular Carcinoma is anticipated to witness rise in incidence rate during the forecast period. HCC is currently expected to be the third leading cause of death worldwide.
Adolescent Drinking Can Cause Liver Problems Later In Life
21 January 2018
Data indicated that alcohol consumption early in life was associated with an increased risk of developing severe liver disease. After 39 years of follow-up, 383 men had developed severe liver disease, which was defined as a diagnosis of liver cirrhosis, decompensated liver disease (Hepatocellular Carcinoma, ascites, esophageal varices, hepatorenal syndrome, or hepatic encephalopathy), liver failure, or death from liver disease.
Study: Marijuana Use Associated With Reduced Prevalence Of Liver Disease In Alcoholics
20 January 2018
“Abusive alcohol use has well-established health risks including causing liver disease (ALD) characterized by alcoholic steatosis (AS), steatohepatitis (AH), fibrosis, cirrhosis (AC) and Hepatocellular Carcinoma (HCC)”, states the study’s abstract. “Strikingly, a significant number of individuals who abuse alcohol also use Cannabis, which has seen increased legalization globally. While cannabis has demonstrated anti-inflammatory properties, its combined use with alcohol and the development of liver disease remains unclear.”
AVEO Oncology’s Tivozanib Shows Positive Effect In Early-Stage Liver Cancer Study
19 January 2018
AVEO Oncology (AVEO +5.4%) is up on 30% higher volume in response to positive results from the Phase 1b portion of a Phase 1b/2 clinical trial assessing lead drug FOTIVDA (tivozanib) in patients with advanced unresectable Hepatocellular Carcinoma (HCC).
Invitrocue’s Onco-PDO Technology Grows Liver Cancer Outside Of Body
17 January 2018
Invitrocue has again validated its Onco-PDO technology by successfully growing liver cancer outside the human body, opening the door for liver cancer sufferers to receive more personalized drug treatment plans. Using Onco-PDO technology, Invitrocue researchers have been able to culture a variety of patient-derived cancer cells in the laboratory. The cultures or organoids can then be tested against a panel of drugs to facilitate personalized drug treatments in patients and improve outcomes.
Exelixis, Ipsen Report Positive Results On Lead Cancer Drug
17 January 2018
Exelixis, Inc. and Ipsen announced positive detailed results from the pivotal phase III CELESTIAL study of Cabometyx (cabozantinib) demonstrating significant overall survival benefit in patients with previously treated advanced Hepatocellular Carcinoma (HCC).
Bayer To Highlight New Research At ASCO GI 2018 Cancer Symposium
17 January 2018
Bayer announced today that new data from the continued research on Stivarga® (regorafenib) and Nexavar® (sorafenib) in advanced liver cancer will be presented at the 2018 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium. The Bayer data include analyses from the RESORCE trial in Hepatocellular Carcinoma (HCC) in addition to the LiverT study in HCC.
Minimally Invasive Liver Resection Reduces Blood Loss, Complications
11 January 2018
Minimally invasive liver resection may be effective for patients with impaired liver function, as results from a recently published study showed that the procedure reduced blood loss and had lower complication rates that led to shorter hospital stays compared with open liver resection. Noda and colleagues retrospectively reviewed the data of 99 patients who underwent hepatectomy for Hepatocellular Carcinoma (n = 96) or combined HCC and cholangiocarcinoma (n = 3).
Married Status May Improve Survival Outcomes In Hepatocellular Carcinoma
5 January 2018
According to a study published in Cancer Management and Research, being married — which may be influenced by race/ethnicity and gender — improved survival outcomes among patients with Hepatocellular Carcinoma (HCC).
First Patient Dosed In Phase 3 Trial Of Beigene’s Therapy Candidate For Advanced Liver Cancer
4 January 2018
Investigators have dosed the first patient in a global Phase 3 trial evaluating the PD-1 inhibitor tislelizumab (BGB-A317) as a first-line therapy for advanced Hepatocellular Carcinoma (HCC) — the most common form of liver cancer — announced BeiGene, the company developing the investigational drug. The trial’s primary goal is to determine if tislelizumab is superior to the current standard of care at improving patient survival. It is part of a collaboration between BeiGene and Celgene, which aims to develop this anti-PD-1 antibody for the treatment of solid tumors.
Netscientific Investee Gets Good Results From Liver Cancer Diagnostic
4 January 2018
In a blind evaluation of 149 Hepatocellular Carcinoma positive patients and control samples, Glycotest’s panel achieved an area under the curve of 0.97 and exhibited 93% sensitivity at 92% specificity, which NetScientific said indicates a high predictability on a statistical basis as to whether liver cancer is present in patients or not.
Beigene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab In Patients With Hepatocellular Carcinoma
2 January 2018
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that in December 2017 the first patient was dosed in a global Phase 3 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, in patients with previously untreated advanced Hepatocellular Carcinoma (HCC or liver cancer). Along with two pivotal Phase 2 trials in China in relapsed/refractory classical Hodgkin lymphoma and urothelial cancer, and a global Phase 3 trial in patients with non-small cell lung cancer, tislelizumab is now being evaluated in pivotal trials in four distinct indications.
Dr. Abou-Alfa On Checkpoint Inhibitors In Liver Cancer
2 January 2018
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses checkpoint inhibitors in liver cancer. There is a place for checkpoint inhibitors in liver cancer, says Ghassan, but currently he chooses tyrosine kinase inhibitor (TKI) therapy. Upcoming data with checkpoint inhibitors will read out soon and will affect sequencing, he adds.
3 Biggest Breakthroughs In Cancer Treatment In 2017
30 December 2017
On April 27, 2017, the FDA approved the first liver cancer drug in over a decade by expanding the use of Bayer AG’s (NASDAQOTH: BAYRY) Stivarga (regorafinib) to include treatment of patients with Hepatocellular Carcinoma who have been previously treated with the drug sorafenib. Prior to this approval, advanced liver cancer patients that stopped responding, or never responded, to Bayer’s first-line drug, sorafenib, had an exceptionally bleak prognosis, with most living less than a year.
Taiwan Study Confirms PM2.5 Pollution Causes Lung Disease, Liver Cancer
28 December 2017
Preliminary findings by a group of Taiwanese government agencies on the effects of excessive PM2.5 (particles suspended in the air less than 2.5 micrometers in diameter) humans include lung disease and liver cancer, while in terms of areas, and central and southern Taiwan are in the most urgent need of air pollution control, reported Apple Daily. Starting in 2015, Taiwan’s National Health Research Institute (NHRI), Health Promotion Administration (HPA), and the Environmental Protection Administration (EPA) and been collaborating a study measuring the long-term health impacts of air pollution on Taiwanese citizens.
BRIEF—Lenvatinib Accepted For Priority Review For Liver Cancer By China’s FDA
27 December 2017
Japanese pharma major Eisai announced today that its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima and Kisplyx) for use in the treatment of Hepatocellular Carcinoma (HCC), which was submitted for approval in China in October 2017, has been designated for priority review and approval by the China Food and Drug Administration (CFDA) due to lenvatinib’s significant clinical benefit compared to existing treatments.
New Treatments For Liver Cancer
27 December 2017
Liver cancer has always been a difficult diagnosis. And today, the number of people who develop liver cancer is increasing, making primary liver (and bile duct) cancer the fastest-rising cause of cancer-related death in the United States. Experts attribute this to the high prevalence of fatty liver disease, a condition associated with insulin resistance, obesity, high blood pressure and high cholesterol levels. The good news is we have newer treatments that are making a significant impact in helping patients with liver and bile duct cancers live longer and with a better quality of life. These new approaches include the latest immunotherapy drugs, a focus on making complicated liver surgery safer for more patients, and using embolization procedures in new ways and new combinations.
Meeting Highlights From 2017: HCV Elimination, Treating Injection Drug Users
27 December 2017
The introduction of direct-acting antivirals was a significant step toward hepatitis C. Physicians, researchers and medical associations have continued to focus on developing methods and programs to treat as many patients with HCV as possible, especially injection drug users who have a high prevalence for transmission. In 2017, experts from around the world discussed the path to HCV elimination and aftercare for successfully treated patients at The Liver Meeting, Digestive Disease Week, the World Congress of Gastroenterology and the International Liver Congress.
Even A Moderate Amount Of Alcohol Can Increase Risk Of Cancer
27 December 2017
We know there are certain things that can increase a person’s risk of cancer, such as smoking. But it turns out even drinking a small amount of alcohol can lead to cancer. A new study from the American Society of Clinical Oncology found that between five and six percent of new cancer and cancer deaths can be attributed to alcohol. “People typically don’t associate drinking beer, wine, and hard liquor with increasing their risk of developing cancer in their lifetimes,” Bruce Johnson, the society’s president, said in a statement. The society found that drinking alcohol led to an increased risk in many types of cancer, including oropharyngeal and larynx cancer, esophageal cancer, Hepatocellular Carcinoma, breast cancer, and colon cancer.
Expert Looks Ahead To Promising Liver Cancer Advancements
21 December 2017
Before 2017, there were minimal advancements in the treatment field of Hepatocellular Carcinoma (HCC), with Nexavar (sorafenib) treatment remaining the standard for about a decade. Two more agents have since been added to the treatment landscape: Stivarga (regorafenib) in April and Opdivo (nivolumab) in September, both of which can be administered in patients following treatment with Nexavar. But other therapies are moving steadily through the pipeline, as well. Lenvima (lenvatinib) was compared with Nexavar in the phase 3 Study 304 trial, a noninferiority study that showed no difference between the two agents in the frontline setting. Moreover, the phase 3 CELESTIAL trial exploring Cabometyx (cabozantinib) in patients who previously received Nexavar was announced to have met the primary endpoint of overall survival. Data are likely to be presented at the 2018 Gastrointestinal Cancers Symposium.
Blue Faery Helps Patients Spread Their Wings After Liver Cancer Diagnosis
21 December 2017
Imagine finding out your loved one is diagnosed with Hepatocellular Carcinoma (HCC), and the only source available to learn about this disease is from a medical textbook. Andrea J. Wilson and her sister, Adrienne Wilson, experienced just that. On May 16, 2001, Adrienne — who Andrea raised from the age of 8 years old — came home from high school experiencing intense pain under her right ribs. Following a visit to the emergency room, physicians discovered tumors in Adrienne’s liver and lungs, a diagnosis that she passed away from just 147 days later at the age of 15.
Liver Cancer Patient Irradiated With Delft Microspheres
21 December 2017
The Netherlands is at the forefront in the development of a new method for cancer treatment involving microspheres with radioactive holmium-166. Researchers from TU Delft recently ameliorated the fabrication method of these spheres, allowing patients abroad to be treated with holmium. Radioisotope holmium-166 decays so quickly that it is a challenge to get the activated material from the nuclear reactor to the hospitalized patient in time. Delft researchers, in collaboration with colleagues from Radboud Medical Centre and a company called Quirem Medical, conceived of a way to load special little spheres as thick as a hair with more radioactivity than was previously possible. The radioisotope-containing spheres were used for the first time last week in Italy in a liver cancer patient.
Singapore And Korea Partner To Improve Liver Cancer Treatment
21 December 2017
A team of scientists and researchers from institutes in Singapore is partnering with the Samsung Medical Center (SMC) Institute of Refractory Cancer Research in Korea with aims to develop the world’s first clinically reliable and robust platform, which can significantly improve the treatment of Hepatocellular Carcinoma (HCC), or liver cancer. The new platform is intended to provide reliable and robust patient-specific diagnostic and predictive data in a clinically relevant timeframe of three weeks (versus three-four months), so patient-derived HCC tumor samples can contribute to genomic integration in vivo model studies and drug screening data. These will be validated to deliver precision analysis and improve patient outcomes.
Checkpoint Inhibitors, Tkis, And Novel Agents Poised To Enter Liver Cancer Treatment Paradigm
19 December 2017
Prior to 2017, the Hepatocellular Carcinoma (HCC) space had little movement in therapeutic advancements beyond standard sorafenib (Nexavar). Two more agents have since been added to the treatment landscape: regorafenib (Stivarga) in April and nivolumab (Opdivo) in September, both of which can be administered in patients following treatment with sorafenib.
Fat Fuels Liver Cancer Cells
18 December 2017
Cancer cells are bad-ass marathoners, outpacing the growth of surrounding cells and going the distance to colonize far-flung parts of the body. So, what’s the fuel of choice for these long-distance foes? Much attention has been paid to sugars, but fats are also favorites. It’s not about what we eat — there’s no evidence that cutting carbs, for instance, will starve cancer cells — it’s more about how the cells themselves are producing these fuels. Now a group led by researchers at the University of Basel in Switzerland has figured out how liver cancer cells acquire their supply of fat. The findings published in Cancer Cell also suggest that drugs that stop fat synthesis could be useful additions to liver cancer therapy.
Can-Fite Reports On The Progress Of Its Phase II Liver Cancer With Namodenoson
18 December 2017
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson (CF102) in the treatment of advanced Hepatocellular Carcinoma (HCC). Ongoing close observation of enrolled subjects indicates a potentially favorable drug safety profile. The Company previously announced in August that it had successfully completed enrollment of 78 patients.
Local Nonprofit Tackles Hepatitis And Liver Cancer In Mongolia
16 December 2017
This past September, October and November, volunteers with the Flagstaff International Relief Effort (FIRE) screened more than 5,000 people for hepatitis and liver cancer in Dornod province in eastern Mongolia. According to FIRE, Mongolia has the highest rate of liver cancer and among the highest rates of hepatitis in the world. The province of Dornod has twice the national average of liver cancer, make it 12 times the international average. “Hepatitis Free Mongolia,” is a collaboration between FIRE, the Flagstaff Rotary Club and the Rotary Club of Ulaanbaatar, funded by Rotary International and the Rotary Foundation.
H3 Biomedicine’s Preclinical Data Highlighting Novel Discovery Research In Hepatocellular Carcinoma
15 December 2017
H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, today announced that data on one of its clinical programs has been published in the current issue of Cancer Research. The title of the paper, “H3B-6527 is a Potent and Selective Inhibitor of FGFR4 in FGF19-driven Hepatocellular Carcinoma,” was composed by H3 scientists with Anand Selvaraj, PhD, Senior Investigator as lead scientist on the study.
Nearly 40% Of Cancer Deaths Are Preventable With Lifestyle Changes
14 December 2017
We know that certain lifestyle choices can increase the risk of cancer, but a new study puts into perspective just how many cancer-related deaths could be stopped by exercising more, drinking less, cutting out smoking, or making other lifestyle changes.
Nuke Med Intervention Safe, Effective Against Advanced Liver Cancer
11 December 2017
Patients who have advanced liver cancer with blockage or narrowing of the blood vessel that brings blood to the liver from the intestines (i.e., portal vein thrombosis) are safely and effectively treated by interventional radiologists administering the isotope yttrium-90 (Y90) for radioembolization, according to a study conducted at Northwestern University and published online Dec. 7 in the Journal of Nuclear Medicine.
TPX2 Suppresses Tumorigenicity In Hepatocellular Carcinoma
10 December 2017
A new study has indicated that targeting TPX2 can suppress tumorigenicity in liver cancer cells, suggesting that this protein is a potential target for anticancer therapy in Hepatocellular Carcinoma. Hepatocellular Carcinoma (HCC) remains one of the most difficult cancers to treat with chemotherapies being relatively ineffective. Cell cycle deregulation is a common event in human cancer and provides several therapeutic strategies to inhibit cancer cell growth. Targeting protein for Xklp2 (TPX2) is a protein required for targeting kinesin-like protein-12 (Xklp2) to the spindle pole in Xenopus egg extracts. It has been found to be over-expressed as a consequence of oncogenic alterations and also alters the proper regulation of chromosome segregation in cancer cells.
In The Spotlight: Adaptimmune Therapeutics
8 December 2017
Adaptimmune Therapeutics PLC has returned 97% this year, while the iShares Nasdaq Biotechnology ETF index, which tracks the investment results of biotechnology and pharmaceutical equities listed on the NASDAQ, is up only 17% year-to-date. Adaptimmune is focused on developing engineered T cell therapies. T cells are a type of white blood cells, which play an important role in the body’s immune system and help fight cancer. T cells have ‘T cell receptors’ on their surface through which they recognize foreign substances (antigens) such as bacteria, a virus or tumor cell, and destroy them.
Genoscience Pharma Receives FDA Approval For Liver Cancer Study
6 December 2017
Genoscience Pharma, a clinical-stage biotechnology company working to discover and develop cancer treatment drugs, announced today that its most advanced compound, GNS561, has received approval from the Food and Drug Administration (FDA) to initiate a Phase Ib/IIa study in patients with advanced hepatocarcinoma (HCC).
What You Need To Know About CRISPR And Liver Cancer
6 December 2017
Cancer that starts in the liver is called primary liver cancer. Hepatocellular Carcinoma, or HCC, is the most common type of primary liver cancer. Some people are surprised to learn that HCC is often caused by hepatitis B and C viruses. Now that hepatitis C virus infections can be cured, Christoph Seeger, PhD, of Fox Chase Cancer Center wants to help make sure that the estimated 257 million people living with chronic hepatitis B don’t get HCC.
Elevated Levels Of HBV DNA And Hbsag May Increase Liver Cancer Risk
4 December 2017
HealthDay News — Elevated levels of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) are associated with increased risks of liver cancer, according to a study published in the Journal of Gastroenterology and Hepatology. Yang Yang, from the Shanghai Jiaotong University School of Medicine in China, and colleagues assessed the potential of HBsAg and viral load to stratify liver cancer risk. They performed a nested case-control study in 211 liver cancer cases and 221 controls who were sero-positive for HBsAg within two population-based cohorts in Shanghai.
Researchers May Have Confirmed Whether HCV Treatment Poses Liver Cancer Risk
3 December 2017
Results from a large cohort study alleviate concerns that direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) could increase risk of Hepatocellular Carcinoma (HCC), while confirming that cirrhosis is a prominent factor in HCC — the fastest growing cause of cancer-related deaths in the US. There had been no consensus on the possibility that DAA treatment could increase risk for HCC as recently as the 2017 International Liver Congress, due to the inconsistent findings from relatively small trials, Raoel Maan, MD, Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam and Jordan Feld, MD, MPH, Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto noted in commentary accompanying the study.
For past liver cancer news, please visit our Liver Cancer News Archives.